These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 18360018)

  • 1. The MUSCAT study: a Multicenter PROBE Study Comparing the Effects of Angiotensin II Type-1 Receptor Blockers on Self-Monitored Home Blood Pressure in Patients with Morning Hypertension: study design and background characteristics.
    Uchida H; Nakamura Y; Kaihara M; Norii H; Hanayama Y; Makino H
    Hypertens Res; 2008 Jan; 31(1):51-8. PubMed ID: 18360018
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy and duration of action of the four selective angiotensin II subtype 1 receptor blockers, losartan, candesartan, valsartan and telmisartan, in patients with essential hypertension determined by home blood pressure measurements.
    Nishimura T; Hashimoto J; Ohkubo T; Kikuya M; Metoki H; Asayama K; Totsune K; Imai Y
    Clin Exp Hypertens; 2005 Aug; 27(6):477-89. PubMed ID: 16081340
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Practical efficacy of telmisartan for decreasing morning home blood pressure and pulse wave velocity in patients with mild-to-moderate hypertension.
    Uchida H; Nakamura Y; Kaihara M; Sugimoto T; Norii H; Sasaki M; Sato H; Makino H
    Hypertens Res; 2004 Aug; 27(8):545-50. PubMed ID: 15492473
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Losartan/hydrochlorothiazide combination therapy surpasses high-dose angiotensin receptor blocker in the reduction of morning home blood pressure in patients with morning hypertension.
    Hanayama Y; Uchida HA; Nakamura Y; Makino H
    Acta Med Okayama; 2012; 66(6):449-59. PubMed ID: 23254579
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antiproteinuric effects of angiotensin receptor blockers: telmisartan versus valsartan in hypertensive patients with type 2 diabetes mellitus and overt nephropathy.
    Galle J; Schwedhelm E; Pinnetti S; Böger RH; Wanner C;
    Nephrol Dial Transplant; 2008 Oct; 23(10):3174-83. PubMed ID: 18450829
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Rationale, design and patient baseline characteristics of OlmeSartan and calcium antagonists randomized (OSCAR) study: a study comparing the incidence of cardiovascular events between high-dose angiotensin II receptor blocker (ARB) monotherapy and combination therapy of ARB with calcium channel blocker in Japanese elderly high-risk hypertensive patients (ClinicalTrials. gov no. NCT00134160).
    Ogawa H; Kim-Mitsuyama S; Jinnouchi T; Matsui K; Arakawa K
    Hypertens Res; 2009 Jul; 32(7):575-80. PubMed ID: 19444280
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of effects of angiotensin II receptor blocker on morning home blood pressure and cardiorenal protection between morning administration and evening administration in hypertensive patients: the COMPATIBLE study.
    Mori H; Yamamoto H; Ukai H; Yuasa S; Nakajima K; Mikawa T; Niizuma M; Hirao K; Umemura S;
    Hypertens Res; 2013 Mar; 36(3):202-7. PubMed ID: 23013888
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Central blood pressure and pulse wave velocity: relationship to target organ damage and cardiovascular morbidity-mortality in diabetic patients or metabolic syndrome. An observational prospective study. LOD-DIABETES study protocol.
    Gómez-Marcos MA; Recio-Rodríguez JI; Rodríguez-Sánchez E; Castaño-Sánchez Y; de Cabo-Laso A; Sánchez-Salgado B; Rodríguez-Martín C; Castaño-Sánchez C; Gómez-Sánchez L; García-Ortiz L
    BMC Public Health; 2010 Mar; 10():143. PubMed ID: 20298558
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of angiotensin II type 1 receptor blocker on ambulatory blood pressure variability in hypertensive patients with overt diabetic nephropathy.
    Masuda S; Tamura K; Wakui H; Kanaoka T; Ohsawa M; Maeda A; Dejima T; Yanagi M; Azuma K; Umemura S
    Hypertens Res; 2009 Nov; 32(11):950-5. PubMed ID: 19713965
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Evaluation of antihypertensive effect of angiotensin II receptor blockers in patients with essential hypertension by self-measured home blood pressure--HACARARE 300 study].
    Msanobu T;
    Nihon Rinsho; 2009 Oct; 67(10):2013-20. PubMed ID: 19860206
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Office and ambulatory pulse pressure--association with clinical characteristics and cardiovascular risk factors in normoalbuminuric patients with type 2 diabetes (ROADMAP study).
    Januszewicz A; Ritz E; Viberti G; Mimran A; Rabelink AJ; Rump LC; Ruilope LM; Katayama S; Ito S; Izzo JL; Haller H
    J Hum Hypertens; 2011 Nov; 25(11):679-85. PubMed ID: 21150933
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A home blood pressure monitoring study comparing the antihypertensive efficacy of two angiotensin II receptor antagonist fixed combinations.
    Bobrie G; Delonca J; Moulin C; Giacomino A; Postel-Vinay N; Asmar R;
    Am J Hypertens; 2005 Nov; 18(11):1482-8. PubMed ID: 16280286
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cardiovascular outcomes in the first trial of antihypertensive therapy guided by self-measured home blood pressure.
    Asayama K; Ohkubo T; Metoki H; Obara T; Inoue R; Kikuya M; Thijs L; Staessen JA; Imai Y;
    Hypertens Res; 2012 Nov; 35(11):1102-10. PubMed ID: 22895063
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparative effects of telmisartan and valsartan as add-on agents for hypertensive patients with morning blood pressure insufficiently controlled by amlodipine monotherapy.
    Yoshida H; Akasaka H; Saitoh S; Shimamoto K; Miura T;
    Hypertens Res; 2014 Mar; 37(3):225-31. PubMed ID: 24108237
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of telmisartan and losartan on cardiovascular protection in Japanese hypertensive patients.
    Hasegawa H; Takano H; Narumi H; Ohtsuka M; Mizuguchi T; Namiki T; Kobayashi Y; Komuro I
    Hypertens Res; 2011 Nov; 34(11):1179-84. PubMed ID: 21796128
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of renin-angiotensin system inhibition on end-organ protection: can we do better?
    Weir MR
    Clin Ther; 2007 Sep; 29(9):1803-24. PubMed ID: 18035185
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of the angiotensin II receptor blockers telmisartan versus valsartan on the circadian variation of blood pressure: impact on the early morning period.
    White WB; Lacourciere Y; Davidai G
    Am J Hypertens; 2004 Apr; 17(4):347-53. PubMed ID: 15062889
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Valsartan Amlodipine Randomized Trial (VART): design, methods, and preliminary results.
    Nakayama K; Kuwabara Y; Daimon M; Shindo S; Fujita M; Narumi H; Mizuma H; Komuro I
    Hypertens Res; 2008 Jan; 31(1):21-8. PubMed ID: 18360014
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Angiotensin II receptor blocker-based therapy in Japanese elderly, high-risk, hypertensive patients.
    Ogawa H; Kim-Mitsuyama S; Matsui K; Jinnouchi T; Jinnouchi H; Arakawa K;
    Am J Med; 2012 Oct; 125(10):981-90. PubMed ID: 22503610
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Renal protection with angiotensin receptor blockers: where do we stand.
    Schmieder RE; Ruilope LM; Barnett AH
    J Nephrol; 2011; 24(5):569-80. PubMed ID: 21404225
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.